This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pantel, K. Articles by Braun, S. Search for Related Content PubMed PubMed Citation Articles by Pantel, K. Articles by Braun, S. Related Collections Clinical Research Clinical Research: Imaging, Diagnosis, and Prognosis

Detection and Clinical Implications of Early Systemic Tumor Cell Dissemination in Breast Cancer

¹ Institut für Tumorbiologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany;
² Frauenklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany;
³ Klinik für Frauenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; and
⁴ Universitätsklinik für Frauenheilkunde, Leopold-Franzens-Universität, Innsbruck, Austria

ABSTRACT

Blood-borne distant metastasis is the leading cause of cancer-related death in breast cancer. The onset of this fundamental process can now be assessed in cancer patients using ultrasensitive immunocytochemical and molecular assays able to detect even single metastatic cells. Analyses of bone marrow (BM) samples show that disseminated cells are present in 20–40% of primary breast cancer patients without any clinical or histopathological signs of metastasis. The common homing of circulating breast cancer cells in BM is indicative for systemic tumor cell spread and predictive for growth of overt metastases in relevant organ sites such as bone, lung, or liver. Recent clinical studies involving more than 3000 breast cancer patients demonstrated that the presence of tumor cells in BM at primary diagnosis is an independent prognostic factor for unfavorable clinical outcome. To date, sampling of BM, however, is not a routine procedure in clinical management of breast cancer patients. Therefore, several research groups have developed sensitive assays for detection of circulating tumor cells in peripheral blood. Studies evaluating the clinical relevance of these blood assays are ongoing. Here, we will review the existing tumor cell assays and discuss their current clinical relevance and perspectives for the clinical management of breast cancer patients.

This article has been cited by other articles:

				I. Langer, U. Guller, O. R. Koechli, G. Berclaz, G. Singer, G. Schaer, M. K. Fehr, T. Hess, D. Oertli, L. Bronz, et al. Association of the Presence of Bone Marrow Micrometastases with the Sentinel Lymph Node Status in 410 Early Stage Breast Cancer Patients: Results of the Swiss Multicenter Study Ann. Surg. Oncol., June 1, 2007; 14(6): 1896 - 1903. [Abstract] [Full Text] [PDF]

				Z. Liu, M. Jiang, J. Zhao, and H. Ju Circulating Tumor Cells in Perioperative Esophageal Cancer Patients: Quantitative Assay System and Potential Clinical Utility Clin. Cancer Res., May 15, 2007; 13(10): 2992 - 2997. [Abstract] [Full Text] [PDF]

				E. I. Chen, J. Hewel, J. S. Krueger, C. Tiraby, M. R. Weber, A. Kralli, K. Becker, J. R. Yates III, and B. Felding-Habermann Adaptation of Energy Metabolism in Breast Cancer Brain Metastases Cancer Res., February 15, 2007; 67(4): 1472 - 1486. [Abstract] [Full Text] [PDF]

				J. Muller-Berghaus, K. Ehlert, S. Ugurel, V. Umansky, M. Bucur, V. Schirrmacher, P. Beckhove, and D. Schadendorf Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. Cancer Res., June 15, 2006; 66(12): 5997 - 6001. [Abstract] [Full Text] [PDF]

				D. N. Krag, R. Kusminsky, E. Manna, A. Ambaye, D. L. Weaver, S. P. Harlow, M. Covelli, M. A. Stanley, L. McCahill, F. Ittleman, et al. The Detection of Isolated Tumor Cells in Bone Marrow Comparing Bright-Field Immunocytochemistry and Multicolor Immunofluorescence Ann. Surg. Oncol., September 1, 2005; 12(9): 753 - 760. [Abstract] [Full Text] [PDF]

				W. Janni, B. Rack, K. Lindemann, and N. Harbeck Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time? Oncologist, August 1, 2005; 10(7): 480 - 492. [Abstract] [Full Text] [PDF]

				O. S. Bruland, H. Hoifodt, G. Saeter, S. Smeland, and O. Fodstad Hematogenous Micrometastases in Osteosarcoma Patients Clin. Cancer Res., July 1, 2005; 11(13): 4666 - 4673. [Abstract] [Full Text] [PDF]

				V. Muller, N. Stahmann, S. Riethdorf, T. Rau, T. Zabel, A. Goetz, F. Janicke, and K. Pantel Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity Clin. Cancer Res., May 15, 2005; 11(10): 3678 - 3685. [Abstract] [Full Text] [PDF]

				S. A. Vantyghem, S. M. Wilson, C. O. Postenka, W. Al-Katib, A. B. Tuck, and A. F. Chambers Dietary Genistein Reduces Metastasis in a Postsurgical Orthotopic Breast Cancer Model Cancer Res., April 15, 2005; 65(8): 3396 - 3403. [Abstract] [Full Text] [PDF]